Factors Affecting the Dose of Cisplatin in Concurrent Chemoradiotherapy with High-Dose Cisplatin for Head and Neck Cancer

2021 ◽  
Vol 114 (2) ◽  
pp. 159-166
Author(s):  
Ryosuke Kitoh ◽  
Yoh-ichiro Iwasa ◽  
Kentaro Mori
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Concurrent Chemoradiotherapy ◽  
High Dose ◽  
Factors Affecting

scholarly journals Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin: A real-world study

2021 ◽  
Author(s):  
Hundo Cho ◽  
Seok Yun Kang ◽  
Hyun Woo Lee ◽  
Yong Won Choi ◽  
Tae-Hwan Kim ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
General Population ◽  
Head And Neck ◽  
Cancer Patients ◽  
Incidence Rate ◽  
Neck Cancer ◽  
Real World ◽  
Concurrent Chemoradiotherapy ◽  
Thromboembolic Events ◽  
Factors Affecting

Abstract Background The risk of thromboembolic events (TEE) in cancer patients, especially those receiving cisplatin-based chemotherapy, is higher than that of general population. Methods The study investigated the incidence of TEE in 257 head and neck (H&N) cancer patients, during or within 6 months of completion of concurrent chemoradiotherapy (CCRT) with cisplatin, and analyzed factors affecting TEE occurrence. Results TEE occurred in 5 patients, an incidence rate of 1.9%. Khorana score was the only factor associated with TEE occurrence (p = 0.010). Conclusions The incidence of TEE in H&N cancer patients who underwent CCRT with cisplatin was relatively low when compared to other types of cancer. However, patients with a high Khorana score require more careful surveillance for possible TEE occurrence.

High dose reirradiation of head and neck cancer

1992 ◽  
Vol 24 ◽  
pp. 245-246
Author(s):  
Kenneth R. Stevens ◽  
Amy Britsch ◽  
William T. Moss
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
High Dose
Sign in / Sign up

Export Citation Format

Share Document